AI assistant
Pasithea Therapeutics Corp. — Director's Dealing 2024
Mar 2, 2024
35389_dirs_2024-03-01_b6812c27-d398-493f-9530-adf8a241f22e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pasithea Therapeutics Corp. (KTTA)
CIK: 0001841330
Period of Report: 2024-03-01
Reporting Person: Schneiderman Daniel H (Chief Financial Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-03-01 | Stock Option (right to buy) | $8.34 | A | 10000 | Acquired | 2034-02-28 | Common Stock (10000) | Direct |
| 2024-03-01 | Stock Option (right to buy) | $8.34 | A | 5927 | Acquired | 2034-02-28 | Common Stock (5927) | Direct |
Footnotes
F1: The option award was made in accordance with the terms of the Issuer's 2023 Stock Incentive Plan (the "2023 Plan"). The shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), underlying the option award will vest at the rate of 33% upon the one-year anniversary of the date of grant and the remaining shares will vest in equal quarterly installments thereafter for the next two years; provided, that the Reporting Person remains in continuous service to the Issuer through such vesting date.
F2: The option award was made in accordance with the terms of the 2023 Plan. The option award fully vested upon issuance and became exercisable on March 1, 2024.